Valeant Pharmaceuticals International, Inc. (TSE:VRX) Stock Rating Reaffirmed by Royal Bank Of Canada

Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank Of Canada in a report released on Wednesday, November 8th, StockTargetPrices.com reports. They presently have a C$23.00 price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 22.34% from the company’s previous close.

Separately, TD Securities increased their target price on Valeant Pharmaceuticals International to C$26.00 and gave the company a “hold” rating in a research report on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of C$22.50.

Shares of Valeant Pharmaceuticals International (TSE VRX) traded up C$0.52 during trading hours on Wednesday, reaching C$18.80. The company had a trading volume of 1,068,200 shares, compared to its average volume of 1,430,540. Valeant Pharmaceuticals International has a 52 week low of C$11.20 and a 52 week high of C$25.22.

COPYRIGHT VIOLATION NOTICE: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://stocknewstimes.com/2017/11/18/valeant-pharmaceuticals-intl-inc-vrx-receives-sector-perform-rating-from-royal-bank-of-canada.html.

In other news, Director Schutter Richard Urbain De bought 4,900 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average price of C$14.35 per share, for a total transaction of C$70,315.00.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Stock Target Prices

Analyst Recommendations for Valeant Pharmaceuticals International (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply